Lyell Immunopharma, Inc. Net Rentable Area
Lyell Immunopharma, Inc. (LYEL) had Net Rentable Area of 11.00 thousand sqft as of 2021-05-31, per its 10-Q filed 2022-08-04.
Discontinued › Notes
us-gaap:NetRentableArea · last filed 2022-08-04
- 2021-05-31: Net Rentable Area 11.00K sqft.
- 2021-04-30: Net Rentable Area 11.00K sqft.
- 2020-05-31: Net Rentable Area 11.00K sqft.
| Period end | Net Rentable Area |
|---|---|
| 2021-05-31 | 11.00K sqft 10-Q · filed 2022-08-04 |
| 2021-04-30 | 11.00K sqft 10-Q · filed 2021-08-12 |
| 2020-05-31 | 11.00K sqft 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |